| Literature DB >> 26713231 |
Yosi Wibowo1, Richard Parsons2, Bruce Sunderland2, Jeffery Hughes2.
Abstract
Background. Diabetes is an emerging chronic disease in developing countries. Its management in developing countries is mainly hospital/clinic based. The increasing diabetes burden in developing countries provides opportunities for community pharmacists to deliver a range of services. Since the management of diabetes requires the patient's own involvement, it is important to gain their views in order to develop pharmacy-based diabetes services. Studies on diabetes patients' views have been limited to developed countries. Objectives. To investigate, within a developing country setting (Indonesia), current use of pharmacy services by type 2 diabetes patients, and to evaluate their views regarding community pharmacists' roles, and the characteristics that influence their views. Methods. A questionnaire survey was conducted within 10 purposefully selected community pharmacies in Surabaya, Indonesia. Each pharmacy recruited approximately 20 patients seeking antidiabetic medications. Usage of pharmacy services was identified using binary responses ('yes'/'no') and views on pharmacists' roles were rated using Likert scales; an open-ended question was used to identify patient perceived priority roles. Logistic regression models were used to determine characteristics associated with patients' views. Results. A total of 196 pharmacy patients with type 2 diabetes responded (58.3% response rate). Most patients used community pharmacies for dispensing (100%) and education on how to use medications (79.6%). There were mixed views towards pharmacists providing services beyond dispensing. The highest priorities identified were from the 'patient education' domain: education on medications (i.e., directions for use (64.5%), storage (26.6%), common/important adverse effects (25.5%)); and the 'monitoring' domain: monitoring medication compliance (37.3%). Patients with higher incomes or who were working were less supportive of these expanded services, whereas patients who previously used a service, those with risk factors for complications or having poor/unknown glycaemic control were more supportive. Conclusions. Community pharmacies in Surabaya, Indonesia in this study were mainly utilised for dispensing. However, many type 2 diabetes patients using these pharmacies report limited monitoring of blood glucose levels and poor glycaemic control, which indicates an opportunity for greater pharmacist involvement. Yet for this to occur, patients' limited expectations of pharmacists roles will need to be broadened. Characteristics influencing these views should inform the development of pharmacy-based diabetes services in the environment of the burgeoning burden of diabetes.Entities:
Keywords: Community pharmacy; Diabetes; Indonesia; Patient views; Pharmacy services
Year: 2015 PMID: 26713231 PMCID: PMC4690368 DOI: 10.7717/peerj.1449
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Patient recruitment data from 10 community pharmacies.
| Pharmacy code | Geographical area | Socio-economic level | Average number of diabetes patients per month | Number of questionnaires distributed | Number of useable questionnaires returned |
|---|---|---|---|---|---|
| Pharmacy 1 | East Surabaya | 2 | 150 | 40 | 21 |
| Pharmacy 2 | Central Surabaya | 1 | 200 | 28 | 18 |
| Pharmacy 3 | East Surabaya | 3 | 70 | 35 | 20 |
| Pharmacy 4 | West Surabaya | 4 | 100 | 32 | 19 |
| Pharmacy 5 | South Surabaya | 3 | 140 | 37 | 20 |
| Pharmacy 6 | Central Surabaya | 2 | 100 | 30 | 20 |
| Pharmacy 7 | South Surabaya | 4 | 100 | 36 | 20 |
| Pharmacy 8 | North Surabaya | 1 | 240 | 31 | 19 |
| Pharmacy 9 | West Surabaya | 3 | 120 | 40 | 20 |
| Pharmacy 10 | North Surabaya | 2 | 100 | 27 | 19 |
|
|
|
|
Demographic data of patient respondents (N = 196).
| Patient demographics | Frequency (%) |
|---|---|
|
| |
| Male | 80 (40.8) |
| Female | 116 (59.2) |
| 60.0 (32–86) | |
|
| |
| Asian | 196 (100.0) |
| Others | 0 (0.0) |
|
| |
| No schooling | 6 (3.1) |
| Primary school | 23 (11.7) |
| Junior high school | 41 (20.9) |
| Senior high school | 71 (36.2) |
| Diploma | 18 (9.2) |
| Bachelor degree | 25 (12.8) |
| Postgraduate degree | 12 (6.1) |
|
| |
| Working full-time (≥40 hours/week) | 53 (27.0) |
| Working part-time (<40 hours/week) | 20 (10.2) |
| Not working | 123 (62.8) |
|
| |
| ≤Rp 2 million | 103 (52.6) |
| >Rp 2 million—5 million | 54 (27.6) |
| >Rp 5 million—10 million | 25 (12.8) |
| >Rp 10 million | 12 (6.1) |
|
| |
| Self-sponsored insurance | 31 (15.8) |
| Employer-sponsored insurance | 56 (28.6) |
| Insurance scheme for the poor/near poor | 9 (4.6) |
| No insurance | 100 (51.0) |
|
| |
| Yes | 74 (37.8) |
| No | 122 (62.2) |
Notes.
Indonesian rupiah
2 missing responses.
Self-reported diabetes and health profile of patient respondents (N = 196).
| Patient diabetes profile | Frequency (%) of ‘yes’ |
|---|---|
|
| 7 (1–42) |
|
| |
| Modifying diet | 173 (88.3) |
| Exercise programme | 123 (62.8) |
| Oral antidiabetic medication | 189 (96.4) |
| Insulin | 44 (22.4) |
|
| 157 (80.1) |
| BMI ≥25 kg/m2 | 88 (44.9) |
| (History of) smoking | 41 (20.9) |
| High cholesterol | 77 (39.5) |
| High blood pressure | 104 (53.6) |
|
| 115 (58.7) |
| Heart disease | 34 (17.3) |
| Eye problems | 52 (26.5) |
| Foot discomfort | 81 (41.3) |
| Foot ulcers | 14 (7.1) |
| Kidney problems | 16 (8.2) |
Notes.
Some missing responses.
BMI, body mass index = weight (kg) divided by height2 (m2); some missing responses.
Respondents responded ‘yes’ for at least one complication/risk factor.
Respondents responded ‘yes’, either for “Do you have high cholesterol?” or “Do you take medications to treat your high cholesterol?”, or for both.
Respondents responded ‘yes’, either for “Do you have high blood pressure?” or “Do you take medications to treat your high blood pressure?”, or for both.
Self-reported monitoring profile of patient respondents (N = 195).
| Patient monitoring | Frequency (%) of ‘yes’ |
|---|---|
|
| |
|
| 56 (28.7) |
|
| 43 (22.1) |
|
| 26 (13.3) |
|
| 53 (27.0) |
| <6.5% | 18 |
| 6.5–8% | 27 |
| >8% | 8 |
|
| |
|
| 74 (37.9) |
|
| |
| Blood sugar | 167 (86.1) |
| Blood pressure | 166 (85.1) |
| Weight | 124 (63.9) |
|
| 65 (33.3) |
|
| |
| Cholesterol | 127 (65.1) |
| Kidney | 84 (43.1) |
| Eyes | 48 (23.2) |
| Feet | 41 (21.0) |
Notes.
self-monitoring of blood glucose
glycosylated haemoglobin
1 missing response.
Number of respondents reported their HbA1c last value.
Patients’ use of community pharmacy services and their views on pharmacists’ roles (N = 196).
| Services | Being used | Being viewed as pharmacist roles |
|---|---|---|
|
| ||
| Prepare medications | 196 (100) | 195 (100) |
| Provide labels with instructions for use | 196 (100) | 195 (100) |
|
| ||
| Disease process | 93 (47.4) | 120 (61.5) |
| Treatment targets | 79 (40.3) | 115 (59.0) |
| Antidiabetic medications: | ||
| Directions for use | 156 (79.6) | 160 (82.1) |
| Use of insulin devices | 27 (61.4) | 142 (72.7) |
| Storage requirements | 93 (47.4) | 144 (73.9) |
| Special precautions to follow | 141 (71.9) | 155 (79.5) |
| Common/important adverse effects | 87 (44.4) | 139 (71.3) |
| Exercise | 66 (33.7) | 96 (49.2) |
| Diet | 84 (42.9) | 101 (51.8) |
| SMBG | 63 (32.1) | 107 (54.9) |
| Prevention/treatment of acute complications | 67 (34.2) | 126 (64.6) |
| Prevention/treatment of chronic complications | 45 (23.0) | 116 (59.5) |
| Need for regular medical monitoring | 48 (24.5) | 97 (49.8) |
| Foot self-care | 35 (17.9) | 95 (48.7) |
| Smoking cessation | 12 (29.3) | 72 (36.7) |
|
| ||
| Monitor compliance with: | ||
| Antidiabetic medications | 100 (51.0) | 127 (65.1) |
| Exercise plan | 62 (31.6) | 102 (52.3) |
| Diet plan | 78 (39.8) | 109 (55.9) |
| Plan for prevention/treatment of chronic complications | 44 (22.4) | 92 (47.2) |
| Scheduled medical monitoring | 38 (19.4) | 96 (49.3) |
| Monitor treatment outcomes: | ||
| Check records on SMBG | 58 (29.6) | 101 (51.8) |
| Carry out blood glucose tests | 58 (29.6) | 113 (58.0) |
| Measure BMI | 40 (20.4) | 89 (45.6) |
| Measure blood pressure | 55 (28.1) | 103 (52.8) |
| Check results on patient laboratory tests | 51 (26.0) | 98 (50.3) |
| Monitor for adverse effects | 63 (32.1) | 110 (56.4) |
|
| ||
| Refer patients if necessary | 69 (35.2) | 110 (56.5) |
Notes.
self-monitoring of blood glucose
body mass index
1 missing response.
The percentage was calculated for patients currently/previously taking insulin (N = 44).
The percentage was calculated for patients currently (or had a history of) smoking (N = 41).
Patients’ open-ended views on priority roles of pharmacists in diabetes care (N = 169).
| Priority services | Number of responses (%) |
|---|---|
|
| |
| Prepare medications | 35 (20.7) |
| Provide labels with instructions for use | 66 (39.1) |
|
| |
| Disease process | 27 (16.0) |
| Antidiabetic medications: | |
| Directions for use | 109 (64.5) |
| Use of insulin devices | 15 (8.9) |
| Storage requirements | 45 (26.6) |
| Special precautions to follow | 37 (18.9) |
| Common/important adverse effects | 50 (25.5) |
| Exercise | 27 (13.8) |
| Diet | 33 (16.8) |
| Prevention/treatment of acute complications | 27 (16.0) |
| Prevention/treatment of chronic complications | 20 (11.8) |
|
| |
| Monitor compliance with: | |
| Antidiabetic medications | 63 (37.3) |
| Monitor treatment outcomes: | |
| Carry out blood glucose tests | 30 (17.8) |
| Measure blood pressure | 25 (14.8) |
| Monitor for adverse effects | 23 (13.6) |
|
| |
| Provide a complete range of medications | 12 (7.1) |
| Information about medications | 16 (9.5) |
Notes.
Responses to an open-ended question:“In your opinion, what are the five most important services that should be provided at pharmacies to assist you with your diabetes?”
From a total 196 respondents, there were 26 missing responses and 1 invalid response, giving a total N = 169.
Services selected by more than 10 respondents.
Odds ratios and 95% confidence intervals of significant characteristics associated with support for ‘patient education’ and ‘monitoring’ by pharmacists.
| Patient education by pharmacists | Monitoring by pharmacists | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| Medications | Exercise | Diet | All education | Compliance | Treatment outcomes | Adverse drug reaction | ||
| Perform clinical testings | Check test results | ||||||||
|
| |||||||||
| Low | 105 | Reference | Reference | Reference | Reference | Reference | Reference | ||
| Moderate | 54 | NS | 0.4 (0.17–0.90) | NS | NS | NS | NS | ||
| High | 37 | 0.3 (0.10–0.72) | 0.3 (0.10–0.80) | 0.3 (0.12–0.61) | 0.3 (0.10–0.68) | 0.3 (0.10–0.72) | 0.2 (0.09–0.53) | ||
|
| |||||||||
| Not working | 123 | Reference | Reference | Reference | Reference | Reference | |||
| Working | 73 | 0.3 (0.15–0.83) | 0.5 (0.24–0.94) | 0.4 (0.21–0.88) | 0.5 (0.24–0.97) | 0.3 (0.15–0.74) | |||
|
| |||||||||
| No | 39 | Reference | |||||||
| Yes | 157 | 3.4 (1.46–8.03) | |||||||
|
| |||||||||
| Good/fair | 23 | Reference | Reference | Reference | |||||
| Poor | 90 | NS | 4.9 (1.20–20.55) | 3.2 (1.05–9.97) | |||||
| Unknown | 83 | 2.3 (1.22–4.51) | 10.2 (2.44–42.95) | 4.3 (1.36–13.57) | |||||
|
| |||||||||
| No |
| Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference |
| Yes | 4.5 (1.79–11.53) | 10.3 (4.6–23.15) | 4.4 (2.30–8.30) | 4.5 (1.60–12.51) | 5.2 (1.79–11.52) | 13.6 (5.21–35.51) | 11.3 (4.51–28.13) | 6.3 (2.82–13.90) | |
Notes.
A composite variable—education related to antidiabetic medications: directions for use, use of insulin devices (calculated only from those currently/previously taking insulin), storage, special precautions and common/important adverse effects; a mean rating ≥5 was used.
A composite variable—all education: disease process, treatment targets, antidiabetic medications, exercise, diet, self-monitoring of blood glucose, prevention/treatment of acute complications, prevention/treatment of chronic complications, need for regular monitoring, foot self-care and smoking cessation (calculated only from those currently, or had a history of, smoking); a mean rating ≥5 was used.
A composite variable—monitoring compliance with: antidiabetic medications, exercise and diet plan, plan for prevention/treatment of complications and scheduled medical monitoring; a mean rating ≥5 was used.
A composite variable—perform clinical testings (measuring blood glucose, blood pressure and BMI); a mean rating ≥5 was used.
A composite variable – check test results (patient self-monitoring records and laboratory data); a mean rating ≥5 was used.
Diabetes (glycaemic) control is a composite variable of hyper/hypoglycaemia symptoms and HbA1c values.
Numbers differ for each endpoint (service).
not significantly different from the reference